ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biomarkers and rheumatoid arthritis (RA)"

  • Abstract Number: 2290 • 2013 ACR/ARHP Annual Meeting

    Global Metabolite Profiling Of Synovial Fluids From Different Forms Of Inflammatory Arthritis For The Identification Of Putative Biomarker In Rheumatoid Arthritis

    Jiwon Hwang1, Joong Kyong Ahn2, Jaejoon Lee1, Inyoung Kim1, Seulkee Lee1, Chan Hong Jeon3, Eun-Mi Koh1 and Hoon-Suk Cha1, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea

    Background/Purpose: Metabolomics is the study of unique chemical fingerprints of specific cellular processes. Metabolite profiling is recently applied in identifying biomarkers in medical research including…
  • Abstract Number: 2289 • 2013 ACR/ARHP Annual Meeting

    Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis

    Michael Mahler1, Gabriella Lakos1, Tyler Webb1, Alvin Yee1, Leendert A. Trouw2 and Pier-Luigi Meroni3, 1Research, INOVA Diagnostics, San Diego, CA, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Int Medicine, University of Milan, Milano, Italy

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the…
  • Abstract Number: 1737 • 2013 ACR/ARHP Annual Meeting

    Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis:  An Exploratory Phase 2 Biomarker Study

    Gerd Burmester1, Patrick Durez2, Galina Shestakova3, Yue Li4, Amanda Wang5, Steve Lewitzky5, Irina Koroleva5, David Lee6 and Wolfgang Hueber7, 1Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2Université Catholique de Louvain, Brussels, Belgium, 3Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, 4IIS, Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharma AG, Cambridge, MA, 6Novartis Pharma AG, Basel, Switzerland, 7Translational Medicine Autoimmunity, Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: The shared epitope (SE) may play a functional role in RA via Th17/interleukin (IL)-17 polarization (Holoshitz et al. FEBS Lett 2011;585:3619-26). Two phase 2…
  • Abstract Number: 1393 • 2013 ACR/ARHP Annual Meeting

    Survivin But Not Fms-Like Tyrosine Kinase Ligand Is Up-Regulated Before Onset Of Rheumatoid Arthritis

    Mikael Brink1, Maria Bokarewa2, Malin Erlandsson3 and Solbritt Rantapää Dahlqvist4, 1Rheumatology, Umeå University, Umea, Sweden, 2Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden, 3Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 4Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden

    Background/Purpose: Presence of antibodies against citrullinated peptides (anti-CCP2) and increased levels of cytokines and chemokines precedes the development of rheumatoid arthritis (RA) by several years.…
  • Abstract Number: 1323 • 2013 ACR/ARHP Annual Meeting

    Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis

    Jung-Soo Song1, You-Jung Ha2, Eun-Jin Kang3, Kwang-Hoon Lee4, Sang-Won Lee5, Yong-Beom Park6, Soo-Kon Lee6 and Sang Tae Choi1, 1Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 3Rheumatology, Busan Medical Center, Busan, South Korea, 4Dongguk University Ilsan Hospital, Goyang, South Korea, 5Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has…
  • Abstract Number: 957 • 2013 ACR/ARHP Annual Meeting

    The Role Of S100A4 As a Biological Marker Of Immune Response In Early Rheumatoid Arthritis

    Lucie Andrés Cerezo1, Klára Prajzlerová2, Martina Remáková1, Herman F. Mann3, Michal Tomcík2, Karel Pavelka4, Jiri Vencovsky2 and Ladislav Senolt2, 1Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Institute of Rheumatology, Prague, Czech Republic, 2Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

    Background/Purpose: We have previously demonstrated that S100A4 is up-regulated in established rheumatoid arthritis (RA) and that S100A4 regulates apoptosis and synthesis of matrix degrading enzymes…
  • Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting

    Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial

    Sophine B. Krintel1, Christian Dehlendorff2, Merete Lund Hetland3, Kim Hørslev-Petersen4, Klaus K. Andersen2, Peter Junker5, Jan Pødenphant6, Torkell Ellingsen7, Palle Ahlqvist8, Hanne M. Lindegaard9, Asta Linauskas10, Annette Schlemmer11, Mette Y. Dam12, Ib Hansen13, Hans Chr Horn14, Anette Jørgensen15, Johnny Raun16, Christian G. Ammitzbøll12, Mikkel Østergaard17, Kristian Stengaard-Pedersen12 and Julia S. Johansen18, 1Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, 2Danish Cancer Society Research Center, Copenhagen, Denmark, 3DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, 5University of Southern Denmark, Odense, Denmark, 6Copenhagen University at Gentofte, Hellerup, Denmark, 7Silkeborg Regional Hospital, Silkeborg, Denmark, 8University of Southern Denmark, Vejle, Denmark, 9Department of Rheumatology, Odense University Hospital, Odense, Denmark, 10Vendsyssel Hospital, Hjørring, Denmark, 11Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 12Arhus University Hospital, Aarhus, Denmark, 13Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 14Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, 15Rheumatology, Arhus University Hospital, Aarhus, Denmark, 16University of Southern Denmark, Graasten, Denmark, 17Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 18Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark

    Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…
  • Abstract Number: 478 • 2013 ACR/ARHP Annual Meeting

    Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients

    René Galien1, Béatrice Vayssière1, Steve de Vos2, Marielle Auberval1, Nick Vandeghinste2, Sonia Dupont1, Philippe Clément-Lacroix1, Philippe Delerive1, Frédéric Vanhoutte2, Reginald Brys2, Annegret Van der Aa2, Luc Van Rompaey2 and Gerben van 't Klooster2, 1Galapagos SASU, Romainville, France, 2Galapagos NV, Mechelen, Belgium

    Background/Purpose: The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that transduce intracellular signaling for cytokines including interleukins and interferons, and…
  • Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting

    High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis

    Claire I. Daien1,2, Sarah Gailhac3, Thibault Mura4, Bernard Combe2, Michael Hahne1 and Jacques Morel5, 1IGMM, CNRS UMR5535, Montpellier, Montpellier, France, 2Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 3Igmm UMR3555, CNRS, Montpellier, France, 4CIC, Hopital Gui De Chauliac, Montpellier, France, 5Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

    Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis.  We studied…
  • Abstract Number: 2123 • 2012 ACR/ARHP Annual Meeting

    Circulating Mir-223 Is Associated with Disease Activity and May Predict the Response to Therapy in Treatment naïve Patients with Early Rheumatoid Arthritis

    Maria Filkova1, Caroline Ospelt1, Serena Vettori2, Ladislav ŠEnolt3, Herman F. Mann4, Beat A. Michel5, Jiri Vencovsky6, Karel Pavelka3, Renate E. Gay1, Steffen Gay1 and Astrid Jüngel2, 1Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, 2Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 3Institute of Rheumatology, Department of Clinical and Experimental Rheumatology of the 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic

    Background/Purpose: Parameters/ predictors of treatment response in patients with early rheumatoid arthritis (ERA) are needed to optimize treatment management based on the expected disease course.…
  • Abstract Number: 1764 • 2012 ACR/ARHP Annual Meeting

    B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease

    Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela Carbonella, Silvia Canestri and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: B cells are involved as central players in the pathogenesis of rheumatoid arthritis (RA). Our aim was to define whether a specific B cell…
  • Abstract Number: 1321 • 2012 ACR/ARHP Annual Meeting

    C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis

    Ernst R. Dow1, Poulabi Banerjee2, Michelle A. Penny1, Eric P. Nantz2, Sergey Stepaniants3, Anne Ho3, Wendy J. Komocsar2, Pierre-Yves Berclaz2 and Robert W. Hoffman1, 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 2Eli Lilly and Company, Indianapolis, IN, 3Covance Genomics Laboratory LLC, Seattle, WA

    Background/Purpose: Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their clinical response to treatment.  Despite considerable research, no…
  • Abstract Number: 2664 • 2012 ACR/ARHP Annual Meeting

    A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab

    Shintaro Hirata1, Douglas J. Haney2, Guy Cavet2, Rebecca Bolce2, Wanying Li2, Nadine Defranoux2, David Chernoff2, Kunihiro Yamaoka1, Kazuyoshi Saito1 and Yoshiya Tanaka1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose : Anti-TNF therapy has become a standard therapeutic strategy for treatment of patients with rheumatoid arthritis (RA).  A validated multi-biomarker disease activity algorithm (MBDA) blood…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology